Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.316 SEK | -0.16% | +2.76% | -22.45% |
Mar. 26 | Transcript : Vivesto AB - Special Call | |
Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Sales 2021 | 28.87M 2.64M | Sales 2022 | 3.04M 278K | Capitalization | 234M 21.33M |
---|---|---|---|---|---|
Net income 2021 | -133M -12.15M | Net income 2022 | -357M -32.61M | EV / Sales 2021 | 37.7 x |
Net cash position 2021 | 86.84M 7.93M | Net cash position 2022 | 134M 12.27M | EV / Sales 2022 | 32.6 x |
P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
Latest transcript on Vivesto AB
1 day | -0.16% | ||
1 week | +2.76% | ||
Current month | +1.77% | ||
1 month | -0.32% | ||
3 months | -14.48% | ||
6 months | +43.96% | ||
Current year | -22.45% |
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.316 | -0.16% | 50 890 |
24-04-18 | 0.3165 | +0.16% | 434,727 |
24-04-17 | 0.316 | +4.64% | 212,212 |
24-04-16 | 0.302 | -2.27% | 743,158 |
24-04-15 | 0.309 | +0.49% | 342,352 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 07:15 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.45% | 15.59M | |
+27.97% | 672B | |
+23.41% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.21% | 211B | |
-0.38% | 203B | |
-9.98% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- VIVE Stock